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Abstract We solved the structure and traced the complete 
active site of the catalytic domain of the human immunodefi- 
ciency virus type 1 integrase (HIV-1 IN) with the F185H 
mutation. The only previously available crystal structure, the 
F185K mutant of this domain, lacks one of the catalytically 
important residues, E152, located in a stretch of 12 disordered 
residues [Dyda et al. (1994) Science 266, 1981-1986]. It is clear, 
however, that the active site of HIV-1 IN observed in either 
structure cannot correspond to that of the functional enzyme, 
since the cluster of three conserved carboxylic acids does not 
create a proper metal-binding site. The conformation of the loop 
was compared with two different conformations found in the 
catalytic domain of the related avian sarcoma virus integrase 
[Bujacz et al. (1995) J. Mol. Biol. 253, 333-346]. Flexibility of 
the active site region of integrases may be required in order for 
the enzyme to assume a functional conformation in the presence 
of substrate and/or cofaetors. 
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1. Introduction 
The retroviral integrase (IN) is one of only three virus-en- 
coded enzymes, essential for the retroviral replication cycle. 
Because IN catalyzes the insertion of viral DNA into many 
sites on host DNA [1-3], this enzyme is an attractive target 
for inhibition of lentiviruses uch as human immunodeficiency 
virus (HIV), the causative agent of acquired immunodefi- 
ciency syndrome (AIDS). Analysis of  the primary structure 
of IN coupled with deletion mutagenesis has indicated that 
this enzyme, consisting of about 290 amino acids, contains 
three structurally important domains [3,4]. Although the 
structure of complete IN is not yet available, crystal structures 
of the catalytic domains of both HIV-1 IN [5] and avian 
sarcoma virus (ASV) IN [6] have been solved. In addition, 
the NMR structure of  the DNA-binding C-terminal domain 
of HIV-1 IN is also available [7,8]. 
A major difference between the structures of HIV-1 IN and 
ASV IN is in the conformation of the active site and the 
presence of metal ligands. In ASV IN, the active site is com- 
pletely ordered, and a divalent cation (Mg 2+ or Mn 2+) can be 
placed and removed [9]. However, a loop containing residues 
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G146--G152 is found in different conformations in crystals 
grown under different conditions (polyethylene glycol (PEG) 
and ammonium sulfate). Although this flexible loop is adja- 
cent to E157, one of the residues required for the enzymatic 
activity, the conformation of the helical segment containing 
E157 is very similar in both cases. In the structure of HIV-1 
IN [5], however, the corresponding loop (residues I141-S153) 
is totally disordered, and the equivalent residue in the active 
site, E152, was not observed. 
A comparison of the structures of these two catalytic do- 
mains indicated that the interactions in the vicinity of K185, a 
residue mutated in HIV-1 IN for solubility reasons, were sim- 
ilar to those near the corresponding H198 in ASV IN [10]. 
This similarity suggested to us that using a histidine rather 
than a lysine residue at 185 would be a more rational way of 
making a soluble catalytic domain of HIV-1 IN, which would 
be even more likely to show interactions imilar to those 
found in the ASV IN. We present here the results of a crystal- 
lographic study of the F185H mutant of HIV-1 IN at 2.6 
resolution. In addition to confirming the intermolecular inter- 
actions involving this mutation, we were able to provide an 
unambiguous tracing of the complete chain in the active site. 
2. Materials and methods 
Expression, purification, and crystallization of the soluble construct 
of the catalytic ore domain of HIV-1 IN have been performed essen- 
tially as described previously [5,11]. The protein was stored at -20°C, 
in a buffer containing 50 mM HEPES, pH 7.5, 1 M NaC1, 0.7% 
CHAPS, 5 mM dithiothreitol, 5 mM I~-mercaptoethanol, and 20% 
glycerol. Just before crystallization experiments were set up, the solu- 
tion was loaded onto a Mono S HR10/10 column (Pharmacia) and 
eluted with a linear gradient of 0-1 M NaCI, in 50 mM MES, pH 5.5, 
1 mM EDTA, 5 mM 13-mercaptoethanol, and 10% glycerol. The pur- 
ified protein was dialyzed in a simplified buffer containing 50 mM 
MES, pH 5.5, 50 mM NaC1, and 5 mM dithiothreitol and concen- 
trated to 10 mg/ml. Crystals were grown using either the sitting drop 
vapor diffusion method or the dialysis button method from protein 
solutions at concentrations from 5 to 8 mg/ml mixed 1:1 with pre- 
cipitation buffer containing 0.1 M sodium cacodylate, pH 6.5, 0.4 M 
ammonium sulfate and 3-9% PEG 8000. Crystals grew to their final 
size of 0.35 ×0.35 × 0.35 mm 3 in several days at 19°C. 
Diffraction data were collected at -165°C on an RAXIS-IIC image 
plate detector, using mirror-monochromated CuKc~ radiation. The 
crystal was transferred from the mother liquor through a layer of 
glycerol-enriched (15%) mother liquor onto a nylon loop, then 
shock-frozen in a nitrogen gas stream. Diffraction intensities were 
processed with DENZO and scaled with SCALEPACK [12]. The iso- 
morphous tructure of the F185K mutant [5] was used directly as the 
initial model. Data with F> 2~(F) were used in refinement with a low- 
resolution cut-off of 10 ]~. The structure refinements were carried out 
using the program PROLSQ [13]. No data were reserved for R-free 
calculations since the two structures were very similar, and we saw no 
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Fig. 1. Stereo view of intermolecular interactions on the dimer interface in the vicinity of the mutated residue, H185 (black) and K185 (white), 
superimposed on the equivalent region in ASV IN (grey). This figure, as well as Fig. 2, was prepared with the program MOLSCRIPT [15]. 
compelling reason to decrease the number of observations used in the 
refinement. The final conventional R factor was 0.200 (Table 1). The 
coordinates have been deposited with the Brookhaven Protein Data 
Bank (code 2itg). 
3. Results and discussion 
As expected, the structure of the F185H mutant of the 
catalytic domain of HIV-1 IN is very similar to the previously 
published structure of the F185K mutant. The catalytic do- 
main of HIV-1 IN is formed by a five-stranded mixed l-sheet 
flanked by six a-helices. The main part of the t-sheet, formed 
by three antiparaUel 13-strands (131,132, and 133), is extended by 
two short parallel 13-strands (134 and 135). On one side of the 13- 
sheet are three short helices (al ,  a2, and a3). The opposite 
side of the 13-sheet is covered by three long antiparallel helices 
(a4, a5, and a6). The long loop between 135 and a4 has a very 
extended conformation. The dimer is created around the crys- 
tallographic 2-fold axis. The interface is formed mainly by the 
a l  helix of one monomer and the ix5 helix of the other mono- 
mer, utilizing predominantly hydrophobic interactions. Resi- 
dues from the 133 strand, which is located deeper within the 
monomer, contribute to the central part of the dimer inter- 
face. 
The F185H mutant of HIV-1 IN was engineered to provide 
rational interactions between molecules of the dimer in the 
Table I 
Data collection and refinement s atistics for HIV IN (F185H) 
Statistics 
Unit cell parameters 
Space group 
R merge (%) 
No. of reflections 
Total (0c(F) cut-off) 14 682 
Unique 5 012 
Used for refinement (2o(F) cut-off) 4400 
Completeness of data (%) 79.8 
No. of atoms 
Protein 1 234 
Water 58 
Resolution range (,~) 10.0-2.6 
R factor 0.200 
Mean B factor 34.16 
r.m.s, deviations from ideality 
a=b=72.40 A, c=65.56 A, 
P3121 
8.5 
Bond (,~) 0.011 
Angle distances (~) 0.032 
Plane restraints (A) 0.013 
Chiral volumes (~3) 0.135 
region where systematic mutagenesis of hydrophobic residues 
established that the F185K mutation produced a soluble IN 
core [5]. Since histidine was found in the structurally equiva- 
lent location in ASV IN, we assumed that placing histidine at 
this site instead of lysine might make the interactions in the 
two enzymes more similar. However, the observed pattern of 
hydrogen bonds did not exactly mimic the arrangement seen 
in ASV IN. The ASV IN histidine creates a good hydrogen 
bond with a main-chain carbonyl oxygen from the neighbor- 
ing molecule, although shifted one residue down the chain. 
This distance, 3.3 A, for NE2-194 to O-110, is similar to 
that observed in the K185 HIV-1 IN construct. On the other 
hand, both HIV-1 IN structures show the side chain of residue 
185 making contact with the same main chain O-105 (Fig. 1). 
The hydrogen bond distance between NE2-185 and O-105 of 
the neighboring monomer in the dimer is 4.31 A,, greater than 
that observed in the previously published HIV-1 IN structure 
in which the NZ-185 to O-105 distance is 2.6 ,~. In spite of the 
reduced strength of the hydrogen bond that was expected to 
stabilize this region, the area near the F185H mutation site 
and the dimer interface as a whole are essentially unchanged. 
It is, therefore, extremely unlikely that the F185H mutation 
played any role in stabilizing the extended conformation of 
the active site loop. 
The interaction between the mutated H185 and the neigh- 
boring monomer is probably more similar to what may occur 
in this location with the native phenylalanine than with the 
lysine found in the other soluble form of HIV-1 IN. In addi- 
tion to the decreased hydrogen bond interaction, we observed 
stacking interactions between the aromatic rings of H185 and 
F181 in the same a-helix. The distance between CE1-185 and 
CZ-181 is 3.14 A. This stacking interaction may also stabilize 
the native protein. A stacking interaction is not observed be- 
tween analogous residues H198 and Y194 in ASV IN, which 
may be due to the slightly different histidine side-chain hydro- 
gen bond conformation. Also, Y194 is more hydrophilic and 
therefore may not require the same stabilization given by n- 
stacking. 
Comparison of the loops in different structures that include 
the third active site residue, E152 (E157 in ASV IN), indicated 
that the last residue where ASV and HIV-1 IN superimpose is 
Q137 (H142 in ASV IN). This is also the point where the 
structures of F185K and F185H diverge. Although the main 
chain of E138 is visible in the former construct, the side chain 
is truncated. At the other end of the loop, the ct-4 helix starts 
at A154 in both HIV-1 IN structures, with good alignment of 
main and side chains. Even for this structure with a fully 
visible loop, the HIV-1 IN a-4 helix is more than one full 
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Fig. 2. Stereo view of residues 124-165 of HIV-I IN (black), superimposed onthe equivalent region (residues 129-174) of the ASV IN crystal- 
lized from PEG (light grey) and from ammonium sulfate (dark grey). 
turn (5 residues) shorter than any comparable ct-4 helix in the 
ASV IN structures. 
The active site loop of HIV-1 IN is stabilized by three 
contacts between side chain residues and a symmetry-mate 
molecule which is not part of the dimer. The major role in 
stabilization is played by a hydrogen bond between Y143 OH 
and E157 OE2, with a distance of 2.97 A. The tyrosine side 
chain was already clearly visible in electron density maps after 
the first run of refinement. Additional stabilization is provided 
by weak interrnolecular hydrogen bonds involving side chains 
of two g!utamine residues, Q146 and Q148, with distances of 
3.4-3.6 A. None of these residues are near the F185H muta- 
tion or immediately adjacent to the active site, nor are they 
involved in formation of the dimer interface. One possible 
explanation of these observations i  that the differences in 
freezing techniques employed in by us and in previous work 
[5] may be responsible for allowing stabilization of the flexible 
loop. 
The visible section of the active site loop in HIV-1 IN is 
more similar to that of ASV IN grown in ammonium sulfate 
than to the crystal form grown in PEG (Fig. 2). The loop is in 
an even more extended conformation i HIV-1 IN, with re- 
sidues 146-153 essentially linear. The main chain can be 
traced completely in the electron density map (Fig. 3), and 
all side chains are visible except the side chains of residues 
Q146 and Q148, which have poor electron density. These 
loops have comparable temperature factors in ASV IN and 
HIV-1 IN. The average B factor of the HIV-1 IN structure is
34.2 .~2, with the loop in the high 60's. The average tempera- 
ture factor of ASV IN crystallized from ammonium sulfate is 
26 ~2, with loop B factors in the 70's. In both HIV-1 IN 
constructs, the C- and N-termini are flexible, but in the struc- 
! 
Fig. 3. Stereo view of an electron density map° covering residues F139-M154 of the catalytic domain of HIV-1 IN. This 2Fo--Fc map, con- 
toured at the 0.90 level, was calculated at 2.6 A resolution after refinement of the model. The density corresponding to the loop is very clear. 
This figure was prepared with the program CHAIN [16]. 
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ture presented here we were able to place four additional 
residues on the N-terminus and one residue on the C-termi- 
nus. 
Despite being able to see all three residues crucial for the 
enzymatic activity of integrase, we suspect hat the conforma- 
tion of the active site does not correspond to that present in 
the active enzyme. The carboxylate groups of D64, D116, and 
E152 are not very close to each other, and in fact the gluta- 
mate points completely away from the other two groups, quite 
different from the structures of ASV IN with cations bound 
[9]. Although an HIV-1 IN crystal structure with bound metal 
cations is not yet available, antibody binding experiments 
show that HIV-1 IN undergoes significant rearrangement 
upon binding of these essential cofactors (Asante-Appiah, E. 
and Skalka, A.M., personal communication). A similar situa- 
tion has been previously reported for the catalytic ore of the 
bacteriophage Mu transposase, in which the third required 
residue is quite far from the other two [14]. Indeed, disorder- 
ing of the active site might be a specific control mechanism for 
these enzymes, and the active site of HIV-1 IN that we ob- 
served most likely differs from that expected in the presence of 
substrates and cofactors. 
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